Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Signal transducer and activator of transcription 2
(
STAT2
) is an essential transcription factor in the type I IFN (IFN-alpha/beta) signal transduction pathway and known for its role in mediating antiviral immunity and cell growth inhibition. Unlike other members of the STAT family, IFNs are the only cytokines known to date that can activate
STAT2
. Given the inflammatory and antiproliferative dual nature of IFNs, we hypothesized that
STAT2
prevents inflammation-induced colorectal and skin carcinogenesis by altering the inflammatory immune response. Contrary to our hypothesis, deletion of
STAT2
inhibited azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis as measured by prolonged survival, lower adenoma incidence, smaller polyps, and less chronic inflammation.
STAT2
deficiency also inhibited 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate-induced skin carcinogenesis as indicated by reduced papilloma multiplicity. A potential mechanism by which
STAT2
promotes carcinogenesis is through activation of proinflammatory mediators. Deletion of
STAT2
decreased azoxymethane/dextran sodium sulfate-induced expression and release of proinflammatory mediators, such as
interleukin-6
and CCL2, and decreased
interleukin-6
release from skin carcinoma cells, which then decreased STAT3 activation. Our findings identify
STAT2
as a novel contributor to colorectal and skin carcinogenesis that may act to increase the gene expression and secretion of proinflammatory mediators, which in turn activate the oncogenic STAT3 signaling pathway.
...
PMID:STAT2 contributes to promotion of colorectal and skin carcinogenesis. 2023 99